Johnson & Johnson (JNJ) — closed signal from September 21, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 20, 2025.
Predicted vs. what happened
What happened
Reached its target in 57 days.
The thesis — published September 21, 2025
JNJ is a steady healthcare name that recently pulled back, and it could recover. The company has raised its dividend for 63 years, and a new FDA approval for TREMFYA in ulcerative colitis could add a bit more growth. Lawsuits are a risk, so patience is smart. If the price can climb back above 180 and hold, that would show the trend is improving and could set up a 3-month move toward the top of its recent range.
Primary drivers
- 63 straight years of dividend raises signal reliable cash to shareholders
- FDA cleared TREMFYA shot to start treatment in ulcerative colitis, adding growth
- Shares dropped and are calming, which can create room for a rebound
- Price usually moves less than the market, helpful in rough periods
How it played out
JNJ: target reached in 57 days
Lyra published JNJ at 175.08 on 2025-09-21 with expected growth of 12%. The thesis pointed to 63 straight years of dividend raises, FDA clearance for TREMFYA in ulcerative colitis, a recent pullback that had started to calm, and lower usual movement than the market.
Inside the window, JNJ reached a peak of 215.19 on 2025-12-15, above the 194.85 target. The target was reached in 57 days. The stock ended the window at 206.37. The thesis played out and then went beyond the published target.
What happened during the window
On 2025-10-14, Johnson & Johnson reported third-quarter sales of $23.99 billion and adjusted earnings of $2.80 per share. The same day, it announced plans to separate its orthopedics business into DePuy Synthes.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.